Thus, blockade of CLEC5A and TLR2 using a bi-specific anti-CLEC5A/TLR2 mAb has the potential to reduce the risk of autoimmunity post-DV infection, and have therapeutic effects in autoimmune diseases by limiting excessive NET formation and persistent inflammasome activation. The gene discussed is CLEC5A; the disease is Autoimmunity.